Projects & Updates

The advent of immunotherapy has transformed cancer treatment but challenged conventional response evaluation frameworks such as RECIST.
While iRECIST addressed pseudoprogression linked to immune‑related flare effects, another phenomenon—true disease acceleration after immunotherapy initiation—has been described as hyperprogressive disease (HPD).

Despite concerning clinical signals suggesting potential harm to a subset of patients, HPD lacks a validated definition and standardised assessment criteria.
This RECIST Hyperprogression project aims to address this gap through systematic data sharing and analysis.
By leveraging pre‑baseline, baseline and post‑baseline imaging, the project seeks to distinguish natural tumour growth from treatment‑induced acceleration.
The ultimate objective is to qualify and quantify HPD, support consensus criteria, and inform future patient selection and trial design.

• Emiliano Calvo, Start Madrid, ES